The company said net U.S. sales of EYLEA decreased in 2023 compared with 2022, citing changing market dynamics that led to lower net selling prices and lower volumes as the main factors. The company also said the August August 2023 launch of EYLEA HD and the subsequent transition of patients to EYLEA HD affected EYLEA volumes.

10-KAnnual reportFiled Feb 5, 2024Period of report Dec 31, 2023Summary published (UTC) Oct 24, 2026

Key points

AI summary

The company said net U.S. sales of EYLEA decreased in 2023 compared with 2022, citing changing market dynamics that led to lower net selling prices and lower volumes as the main factors. The company also said the August August 2023 launch of EYLEA HD and the subsequent transition of patients to EYLEA HD affected EYLEA volumes.
Regeneron's share of profits from antibody commercialization increased in 2023 compared with 2022. The company said the increase was driven by higher profits from Dupixent sales, partly offset by the impact of the LCA amendment. The company also said it earned the final $50.0 million sales-based milestone from Sanofi in 2023.
The company said stock-based compensation expense included in operating expenses was $885.0 million in 2023 and $725.0 million in 2022. It also disclosed that, as of December 31, 2023, unrecognized compensation expense was $589.6 million for stock options and $1.127 billion for restricted stock.
The company said that as of December 31, 2023 it had no borrowings under its $750.0 million revolving credit facility (the 2022 Credit Facility), and that $1.531 billion remained available under the $3.0 billion share repurchase program approved as of January 2023. The company also said it expects capital expenditures of $825 million to $950 million in 2024.

Key figures

Fiscal year ended December 31, 2023

Revenue: $13.1B
Operating income: $4.0B
Net income: $4.0B
EPS: $34.77
Operating cash flow: $4.6B

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

EYLEA U.S. Net Sales Decline and EYLEA HD Launch

The company said net U.S. sales of EYLEA decreased in 2023 compared with 2022, citing changing market dynamics that led to lower net selling prices and lower volumes as the main factors. The company also said the August August 2023 launch of EYLEA HD and the subsequent transition of patients to EYLEA HD affected EYLEA volumes.

Source · Based on the MD&A text of the filing

Sanofi Antibody Collaboration Profit Share Increase and Milestones

Regeneron's share of profits from antibody commercialization increased in 2023 compared with 2022. The company said the increase was driven by higher profits from Dupixent sales, partly offset by the impact of the LCA amendment. The company also said it earned the final $50.0 million sales-based milestone from Sanofi in 2023.

Source · Based on the MD&A text of the filing

2023 Stock-Based Compensation and Unrecognized Compensation Cost

The company said stock-based compensation expense included in operating expenses was $885.0 million in 2023 and $725.0 million in 2022. It also disclosed that, as of December 31, 2023, unrecognized compensation expense was $589.6 million for stock options and $1.127 billion for restricted stock.

Source · Based on the MD&A text of the filing

Credit Facility, Remaining Buyback Authorization, and 2024 Capital Expenditures as of 2023 Year-End

The company said that as of December 31, 2023 it had no borrowings under its $750.0 million revolving credit facility (the 2022 Credit Facility), and that $1.531 billion remained available under the $3.0 billion share repurchase program approved as of January 2023. The company also said it expects capital expenditures of $825 million to $950 million in 2024.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.